📊 ALEC Key Takeaways
Is Alector, Inc. (ALEC) a Good Investment?
Alector is a pre-revenue stage biotech company with severe operational losses (-$142.9M net loss on only $21.0M revenue) and dramatically negative profitability metrics (net margin of -679.2%). The company is burning cash at an unsustainable rate (-$184.1M operating cash flow) with only 3.6 years of cash runway at current burn, indicating imminent financing risk or liquidation pressure.
Alector's fundamentals are extremely weak: revenue is flat at a low base while operating and net losses remain very large relative to sales, producing deeply negative margins and returns on capital. Although near-term liquidity appears adequate with a 3.83x current ratio, the combination of heavy operating cash burn, negative free cash flow, and a thin equity base materially weakens financial health and growth quality.
Why Buy Alector, Inc. Stock? ALEC Key Strengths
- Strong liquidity position with $65.8M cash and 3.83x current ratio providing near-term operational flexibility
- Modest long-term debt burden with 0.33x debt-to-equity ratio limiting financial leverage risk
- Recent insider activity (8 Form 4 filings in 90 days) suggests active management engagement
- Near-term liquidity is solid, with cash of $65.80M and a 3.83x current and quick ratio
- Balance sheet debt is limited, with long-term debt of $10.00M and debt/equity of 0.33x
- Asset base of $293.24M provides some operating flexibility despite losses
ALEC Stock Risks: Alector, Inc. Investment Risks
- Catastrophic cash burn rate of $184M annually with only $65.8M cash remaining - company faces critical funding necessity within 4 quarters
- Revenue generation appears minimal ($21M) and flat YoY, insufficient to offset R&D/operating expenses in biotech development stage
- Operating losses of $156M with net margin of -679% indicate no clear path to profitability without significant revenue inflection or major asset sale
- Negative free cash flow of -$184.1M demonstrates company cannot fund operations from internal operations and is entirely dependent on external financing
- Operating margin of -741.3% and net margin of -679.2% indicate an unsustainable profitability profile
- Operating cash flow of -$184.03M and free cash flow of -$184.07M point to severe cash burn
- Stockholders' equity of only $30.65M versus cumulative losses raises balance sheet fragility and funding risk
Key Metrics to Watch
- Cash balance depletion rate and runway until next financing event
- Clinical trial progress and pipeline advancement toward revenue-generating approvals
- Quarterly revenue growth trajectory and any evidence of commercial traction
- Operating expense burn rate and management's cost control actions
- Quarterly cash burn relative to cash and equivalents
- Revenue growth and operating loss reduction
Alector, Inc. (ALEC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.83x current ratio provides a solid financial cushion.
ALEC Profit Margin, ROE & Profitability Analysis
ALEC vs Healthcare Sector: How Alector, Inc. Compares
How Alector, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Alector, Inc. Stock Overvalued? ALEC Valuation Analysis 2026
Based on fundamental analysis, Alector, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Alector, Inc. Balance Sheet: ALEC Debt, Cash & Liquidity
ALEC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Alector, Inc.'s revenue has declined by 51% over the 5-year period, indicating business contraction. The most recent EPS of $-1.23 indicates the company is currently unprofitable.
ALEC Revenue Growth, EPS Growth & YoY Performance
ALEC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.3M | -$30.5M | $-0.34 |
| Q2 2025 | $7.9M | -$30.5M | $-0.30 |
| Q1 2025 | $3.7M | -$36.1M | $-0.38 |
| Q3 2024 | $9.1M | $1.4M | $-0.43 |
| Q2 2024 | $15.1M | $1.4M | $0.02 |
| Q1 2024 | $15.9M | -$36.1M | $-0.38 |
| Q3 2023 | $9.1M | $1.4M | $-0.53 |
| Q2 2023 | $56.2M | $1.4M | $0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Alector, Inc. Dividends, Buybacks & Capital Allocation
ALEC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Alector, Inc. (CIK: 0001653087)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALEC
What is the AI rating for ALEC?
Alector, Inc. (ALEC) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALEC's key strengths?
Claude: Strong liquidity position with $65.8M cash and 3.83x current ratio providing near-term operational flexibility. Modest long-term debt burden with 0.33x debt-to-equity ratio limiting financial leverage risk. ChatGPT: Near-term liquidity is solid, with cash of $65.80M and a 3.83x current and quick ratio. Balance sheet debt is limited, with long-term debt of $10.00M and debt/equity of 0.33x.
What are the risks of investing in ALEC?
Claude: Catastrophic cash burn rate of $184M annually with only $65.8M cash remaining - company faces critical funding necessity within 4 quarters. Revenue generation appears minimal ($21M) and flat YoY, insufficient to offset R&D/operating expenses in biotech development stage. ChatGPT: Operating margin of -741.3% and net margin of -679.2% indicate an unsustainable profitability profile. Operating cash flow of -$184.03M and free cash flow of -$184.07M point to severe cash burn.
What is ALEC's revenue and growth?
Alector, Inc. reported revenue of $21.0M.
Does ALEC pay dividends?
Alector, Inc. does not currently pay dividends.
Where can I find ALEC SEC filings?
Official SEC filings for Alector, Inc. (CIK: 0001653087) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALEC's EPS?
Alector, Inc. has a diluted EPS of $-1.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ALEC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Alector, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ALEC stock overvalued or undervalued?
Valuation metrics for ALEC: ROE of -466.3% (sector avg: 15%), net margin of -679.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ALEC stock in 2026?
Our dual AI analysis gives Alector, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALEC's free cash flow?
Alector, Inc.'s operating cash flow is $-184.0M, with capital expenditures of $41.0K. FCF margin is -874.7%.
How does ALEC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -679.2% (avg: 12%), ROE -466.3% (avg: 15%), current ratio 3.83 (avg: 2).